Announcing Olink® Explore HT – A New Era in Proteomics
12 Juillet 2023 - 3:00PM
Olink Holding AB (publ) (Nasdaq: OLK) today announced the
introduction of
Olink®
Explore HT, a transformational solution for
high-throughput proteomics delivering unmatched specificity,
scalability, and workflow simplicity.
Olink Explore HT represents a significant
advancement in next generation proteomics, allowing scientists to
accurately measure over 5,300 proteins using only 2µl of sample
with a completely reimagined and streamlined
workflow, including a highly automated data analysis platform.
In addition to delivering over 80% more unique protein assays than
the previous generation product, Olink Explore HT increases sample
throughput by 4X and data output by 7X with a >30% reduction in
cost per data point and >20% reduction in workflow processing
cost. Importantly, these innovations substantially reduce the
environmental footprint with a 6-fold decrease in components and
10-fold reduction in boxes.
“Olink Explore HT demonstrates our unwavering
commitment to innovation and delivering the most powerful solutions
for scientific research,” said Jon Heimer, CEO of
Olink. “The power and capability of Olink Explore HT
seemed almost unthinkable just a handful of years ago. This is the
most advanced high-throughput proteomics product Olink has ever
offered, and the unmatched performance will empower new discoveries
critical for 21st century healthcare.”
Olink Explore HT was designed to unlock the
immense value of proteomics at any scale and advance multi-omic
research. It can be utilized across a wide range of therapeutic
areas to deepen current understanding of molecular pathways
involved in the development, progression, and outcome of disease.
Olink Explore HT will also empower new discoveries in drug
development, from target discovery based on identification of
proteins causal in disease, to actionable insights into mode of
action studies and repurposing of therapeutics from reinterrogation
of existing samples from clinical trials.
“We are very excited about the new Olink Explore
HT platform. With Olink’s transformative multiplex
PEA™ technology, Olink Explore HT allows us to perform
high-throughput, highly multiplexed and extremely precise protein
analysis from minute amounts of clinical sample,” said Ulf
Gyllensten, Professor of Medical Molecular Genetics at Uppsala
University, Sweden. “Coupling PEA with an NGS readout
conveys Olink Explore HT with unprecedented power to unveil the
human proteome. As early access users, we have successfully used
the platform to identify diagnostic and prognostic biomarkers for
gynecological cancer. The expanded set of proteins available for
analysis with Olink Explore HT will certainly accelerate the
discovery of other novel biomarkers and reveal important new
biological insights. More broadly, the platform unlocks a powerful
multiomics-based approach across the entire drug development
process, from basic to translational research.”
Olink Explore HT represents the latest
innovation in combining Olink PEA technology with NGS readout of
relative protein concentrations. Each thoroughly validated assay
maintains the exceptional standards of specificity and sensitivity
that Olink users have come to trust.
More details are available on the Olink
website.
For more information please contact:
IR contact Jan Medina, CFA, VP
Investor Relations & Capital Markets, OlinkMobile: +1 617 802
4157jan.medina@olink.com
Media contact Michael B.
Gonzales, PhD, VP Global Marketing, Olink Mobile: +1 415 308
6467michael.gonzales@olink.com
About OlinkOlink Holding AB
(publ) (Nasdaq: OLK) is a company dedicated to accelerating
proteomics together with the scientific community, across multiple
disease areas to enable new discoveries and improve the lives of
patients. Olink provides a platform of products and services which
are deployed across major biopharmaceutical companies and leading
clinical and academic institutions to deepen the understanding of
real-time human biology and drive 21st century healthcare through
actionable and impactful science. The Company was founded in 2016
and is well established across Europe, North America, and Asia.
Olink is headquartered in Uppsala, Sweden.
Forward-looking statementsThis
press release contains forward-looking statements that are based on
management’s beliefs and assumptions and on information currently
available to management. All statements contained in this release
other than statements of historical fact are forward-looking
statements, including any statements regarding our 2023 revenue
outlook our ability to develop, commercialize and achieve market
acceptance of our current and planned products and services, our
research and development efforts, and other matters regarding our
business strategies, use of capital, results of operations and
financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the
words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under the caption "Risk Factors" in our
Form 20-F (Commission file number 001-40277) and elsewhere in the
documents we file with the Securities and Exchange Commission from
time to time. We caution you that forward-looking statements are
based on a combination of facts and factors currently known by us
and our projections for the future, about which we cannot be
certain. As a result, the forward-looking statements may not prove
to be accurate. The forward-looking statements in this press
release represent our views as of the date hereof. We undertake no
obligation to update any forward-looking statements for any reason,
except as required by law.
A photo accompanying this announcement is available
at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9f3c881c-f181-49b2-8882-16a3bcd5764c
Olink Holding AB (NASDAQ:OLK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Olink Holding AB (NASDAQ:OLK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024